AU2007201553B8 - Expression system - Google Patents

Expression system Download PDF

Info

Publication number
AU2007201553B8
AU2007201553B8 AU2007201553A AU2007201553A AU2007201553B8 AU 2007201553 B8 AU2007201553 B8 AU 2007201553B8 AU 2007201553 A AU2007201553 A AU 2007201553A AU 2007201553 A AU2007201553 A AU 2007201553A AU 2007201553 B8 AU2007201553 B8 AU 2007201553B8
Authority
AU
Australia
Prior art keywords
domain
domains
gst
reagent
protective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007201553A
Other languages
English (en)
Other versions
AU2007201553A1 (en
AU2007201553B2 (en
Inventor
Leslie William James Baillie
Helen Lisa Bullifent
Helen Claire Flick-Smith
Paula Thomson Holden
Julie Miller
Richard William Titball
Andrew William Topping
Nicola Jane Walker
Ethel Diane Williamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2001269305A external-priority patent/AU2001269305B2/en
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Publication of AU2007201553A1 publication Critical patent/AU2007201553A1/en
Application granted granted Critical
Publication of AU2007201553B2 publication Critical patent/AU2007201553B2/en
Publication of AU2007201553B8 publication Critical patent/AU2007201553B8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007201553A 2000-07-08 2007-04-05 Expression system Ceased AU2007201553B8 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0016702.3A GB0016702D0 (en) 2000-07-08 2000-07-08 Expression system
GB0016702.3 2000-07-08
PCT/GB2001/003065 WO2002004646A1 (en) 2000-07-08 2001-07-06 Expression system
AU2001269305A AU2001269305B2 (en) 2000-07-08 2001-07-06 Expression system

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2001269305A Division AU2001269305B2 (en) 2000-07-08 2001-07-06 Expression system

Publications (3)

Publication Number Publication Date
AU2007201553A1 AU2007201553A1 (en) 2007-05-03
AU2007201553B2 AU2007201553B2 (en) 2010-04-22
AU2007201553B8 true AU2007201553B8 (en) 2010-06-03

Family

ID=9895205

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007201553A Ceased AU2007201553B8 (en) 2000-07-08 2007-04-05 Expression system

Country Status (10)

Country Link
US (3) US7537771B2 (enExample)
EP (2) EP1808489B1 (enExample)
JP (2) JP2004502460A (enExample)
CN (2) CN101012458A (enExample)
AU (1) AU2007201553B8 (enExample)
CA (2) CA2658217A1 (enExample)
GB (1) GB0016702D0 (enExample)
RU (2) RU2385348C2 (enExample)
WO (1) WO2002004646A1 (enExample)
ZA (1) ZA200210206B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2004024067A2 (en) * 2002-09-10 2004-03-25 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
AU2003303307B2 (en) * 2002-11-15 2006-12-07 Gen-Probe Incorporated Assay and compositions for detection of bacillus anthracis nucleic acid
WO2005026203A2 (en) 2003-09-18 2005-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna promoters and anthrax vaccines
FR2860005A1 (fr) * 2003-09-23 2005-03-25 Univ Aix Marseille Ii Methode de detection d'agents bacteriens ou viraux de bioterrorisme
WO2005030991A1 (fr) * 2003-09-23 2005-04-07 Universite De La Mediterranee (Aix-Marseille Ii) Methode de detection d’agents bacteriens ou viraux de bioterrorisme
GB0401036D0 (en) * 2004-01-17 2004-02-18 Royal Holloway University Of L Improvements in or relating to vaccination
US8101735B2 (en) 2004-06-16 2012-01-24 Health Protection Agency Preparation of protective antigen
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
CN100336908C (zh) * 2004-09-10 2007-09-12 中国人民解放军军事医学科学院微生物流行病研究所 一种制备重组炭疽保护性抗原的方法及其专用表达质粒
WO2006068647A1 (en) * 2004-12-20 2006-06-29 United States Army Medical Research And Materiel Command Internal positive control for probe-based nucleic acid molecule assays and methods of making and using thereof
GB0504940D0 (en) * 2005-03-10 2005-04-20 Secr Defence Vaccine formulation
WO2008048289A2 (en) 2005-11-14 2008-04-24 University Of Maryland Biotechnology Institute Off. Of Research Admin./Tech. Dev. Salmonella based oral vaccines for anthrax
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
US20070202117A1 (en) * 2005-12-22 2007-08-30 Herman Groen Compositions and Methods Of Modulating the Immune Response
GB0607462D0 (en) 2006-04-13 2006-05-24 Avecia Ltd Assay
JP2008231063A (ja) * 2007-03-22 2008-10-02 Takano Foods Kk 納豆菌ワクチン
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CA2964910C (en) 2007-04-27 2018-01-09 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2010038076A1 (en) * 2008-10-02 2010-04-08 Pharmathene Uk Limited Anthrax vaccine formulation and uses thereof
WO2010080188A2 (en) * 2008-10-14 2010-07-15 The Regents Of The University Of Michigan Epitope targeted anthrax vaccine
US20100183675A1 (en) * 2009-01-22 2010-07-22 Allan Watkinson Stable vaccine compositions and methods of use
US8187611B2 (en) * 2009-10-29 2012-05-29 Albert Einstein College Of Medicine Of Yeshiva University Anti-peptide antibodies that cross react with protective antigen of Bacillus anthracis and uses thereof
US20110110968A1 (en) * 2009-11-12 2011-05-12 Stanley Goldman Human optimized Bacillus anthracis protective antigen
CN101798565B (zh) * 2010-02-26 2013-08-07 中国人民解放军军事医学科学院生物工程研究所 能在芽孢表面展示pa20蛋白的炭疽芽孢杆菌及其应用
RU2633504C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E.coli - продуцент полноразмерного протективного антигена Bacillus anthracis в форме вирусоподобных частиц
RU2633508C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E. coli - продуцент изолированного домена 1 протективного антигена Bacillus anthracis в форме вирусоподобных частиц
WO2020116686A1 (ko) * 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
WO2000002522A2 (en) * 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Anthrax vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2115433C1 (ru) * 1992-08-28 1998-07-20 Научно-исследовательский институт микробиологии МО РФ Вакцина сибиреязвенная комбинированная
RU2110575C1 (ru) * 1995-07-19 1998-05-10 Государственное Федеральное предприятие Государственный научный центр прикладной микробиологии Рекомбинантная плазмидная днк pro pf 5, определяющая синтез капсульного антигена fi возбудителя чумы и протективного антигена возбудителя сибирской язвы, и способ конструирования рекомбинантной плазмидной днк pro pf5
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
WO2000002522A2 (en) * 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Anthrax vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROSSIER FABIEN ET AL: "Role of toxin functional domains in anthrax pathogenesis. " INFECTION AND IMMUNITY, vol. 68, no. 4, Apri 1 2000, pages 1781-1786 *
CIRINO NICK M ET AL: "Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. vol. 67, no. 6, June 1999, pages 2957-2963 *
GUPTA P ET AL: "Expression and Purification of the Recombinant Protective Antigen of Bacillus anthracis" PROTEIN EXPRESSION AND PURIFICATION, vol. 16, no. 3, August 1999, pages 369-376, *
LITTLE S F ET AL: "LOCATION OF RECEPTOR-BINDING REGION OF PROSPECTIVE ANTIGEN FROM BACILLUS ANTHRACIS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 180, no. 2, 31 October 1991, pp531-537 *
SINGH Y ET AL: "A DELETED VARIANT OF BACILLUS ANTHRACIS PROTECTIVE ANTIGEN IS NON- TOXIC AND BLOCKS ANTHRAX TOXIN ACTION IN VIVO" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 32, pp19103-19107 *

Also Published As

Publication number Publication date
RU2270865C2 (ru) 2006-02-27
AU6930501A (en) 2002-01-21
ZA200210206B (en) 2004-03-17
CN1322134C (zh) 2007-06-20
US8313928B2 (en) 2012-11-20
US9346860B2 (en) 2016-05-24
AU2007201553A1 (en) 2007-05-03
CA2413045A1 (en) 2002-01-17
EP1808489B1 (en) 2016-03-23
WO2002004646A1 (en) 2002-01-17
US20100266639A1 (en) 2010-10-21
JP2004502460A (ja) 2004-01-29
EP1808489A1 (en) 2007-07-18
US20030170263A1 (en) 2003-09-11
AU2007201553B2 (en) 2010-04-22
JP2012010706A (ja) 2012-01-19
CA2658217A1 (en) 2002-01-17
GB0016702D0 (en) 2000-08-23
CA2413045C (en) 2016-06-21
US20130164823A1 (en) 2013-06-27
CN101012458A (zh) 2007-08-08
RU2004134341A (ru) 2006-05-10
RU2385348C2 (ru) 2010-03-27
US7537771B2 (en) 2009-05-26
CN1440459A (zh) 2003-09-03
EP1301606A1 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
AU2007201553B8 (en) Expression system
JP2981286B2 (ja) 破傷風トキシンフラグメントｃの発現
KR100338894B1 (ko) 백신조성물
CN102276730B (zh) 金黄色葡萄球菌IsdBid-TRAP融合蛋白制备方法及其应用
US6610300B1 (en) Clostridium perfringens vaccine
Kansau et al. Heat shock proteins of Helicobacter pylori.
EP1724342B1 (en) Process for preparing variant of erysipelothrix rhusiopathiae surface protective antigen in e. coli
US6287566B1 (en) Protective peptides neurotoxin of C. botulinum
CN109942718B (zh) 一种无毒性破伤风毒素和产气荚膜梭菌β毒素重组融合蛋白
Zakowska et al. Protective antigen domain 4 of Bacillus anthracis as a candidate for use as vaccine for anthrax
NO301175B1 (no) Fremgangsmåte for fremstilling av subenhetsprotein fra koleratoksin (CTB) eller hybrid CTB gen-fusjonsprotein
EP2471550A1 (en) Proteins with improved solubility and methods for producing and using same
AU2001269305B2 (en) Expression system
EP0502016B1 (en) Novel vaccine
KR20180130217A (ko) GnRH가 삽입된 STF2 재조합 단백질 및 이의 용도
WO2006011151A2 (en) Vaccine comprising recombinant ct or lt toxin
US20030185850A1 (en) Protective peptides neurotoxin of C. botulinum
AU2001269305A1 (en) Expression system
Wang et al. Preparation of a peptide vaccine against GnRH by a bioprocess system based on asparaginase
Himanen et al. The 20 kDa C-terminally truncated form of pertussis toxin subunit S1 secreted from Bacillus subtilis
JP2007510413A (ja) コレラ毒素のｂサブユニットのための発現システム
JP3654512B2 (ja) 防御組換えｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ（インフルエンザ菌）高分子量タンパク質をコードする核酸分子、形質転換ベクター、形質転換菌株ならびにそれらを用いたタンパク質の生産方法
Counc Outer membrane protein epitopes of Haemophilus influenzae; fusion protein expression in Escherichia coil: application to recombinant vaccine and antibody production, and in the production of reagents for diagnosis

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 24, NO 16, PAGE(S) 1841 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME THE SECRETARY OF STATE FOR DEFENCE, APPLICATION NO. 2007201553, UNDER INID (72) CORRECT THE COINVENTOR TO READ WILLIAMSON, ETHEL DIANE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired